These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28088769)

  • 1. Ultradeep sequencing detection of the R263K integrase inhibitor drug resistance mutation.
    Jaffré J; Armenia D; Bellocchi MC; Wirden M; Carioti L; Lambert S; Valantin MA; Nguyen T; Simon A; Katlama C; Andreoni M; Perno CF; Calvez V; Ceccherini-Silberstein F; Marcelin AG; Todesco E
    J Antimicrob Chemother; 2017 May; 72(5):1537-1539. PubMed ID: 28088769
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada.
    Ji H; Patterson A; Taylor T; Rank C; Halverson J; Capina R; Brooks J; Sandstrom P
    J Acquir Immune Defic Syndr; 2018 May; 78(1):e1-e3. PubMed ID: 29424788
    [No Abstract]   [Full Text] [Related]  

  • 3. Two cases of dolutegravir failure with R263K mutation.
    Cardoso M; Baptista T; Diogo I; Aleixo MJ; Marques N; Mansinho K; Gomes P
    AIDS; 2018 Nov; 32(17):2639-2640. PubMed ID: 30379690
    [No Abstract]   [Full Text] [Related]  

  • 4. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
    Bar-Magen T; Donahue DA; McDonough EI; Kuhl BD; Faltenbacher VH; Xu H; Michaud V; Sloan RD; Wainberg MA
    AIDS; 2010 Sep; 24(14):2171-9. PubMed ID: 20647908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
    Charpentier C; Descamps D
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29346270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to inhibitors of the human immunodeficiency virus type 1 integration.
    Hazuda DJ
    Braz J Infect Dis; 2010; 14(5):513-8. PubMed ID: 21221483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of the R263K mutation to dolutegravir in cerebrospinal fluid HIV-1 virus in one patient with HIV-associated neurocognitive disorders.
    Vassallo M; De Monte A; Durant J; Dunais B; Cottalorda J
    AIDS; 2016 Sep; 30(14):2257-8. PubMed ID: 27574797
    [No Abstract]   [Full Text] [Related]  

  • 14. Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
    Pham HT; Alves BM; Yoo S; Xiao MA; Leng J; Quashie PK; Soares EA; Routy JP; Soares MA; Mesplède T
    J Antimicrob Chemother; 2021 Feb; 76(3):639-647. PubMed ID: 33184634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
    Seatla KK; Choga WT; Mogwele M; Diphoko T; Maruapula D; Mupfumi L; Musonda RM; Rowley CF; Avalos A; Kasvosve I; Moyo S; Gaseitsiwe S
    PLoS One; 2019; 14(11):e0224292. PubMed ID: 31751353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
    Ceccherini-Silberstein F; Malet I; Fabeni L; Dimonte S; Svicher V; D'Arrigo R; Artese A; Costa G; Bono S; Alcaro S; Monforte Ad; Katlama C; Calvez V; Antinori A; Marcelin AG; Perno CF
    J Antimicrob Chemother; 2010 Nov; 65(11):2305-18. PubMed ID: 20817922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.
    Charpentier C; Laureillard D; Piketty C; Tisserand P; Batisse D; Karmochkine M; Si-Mohamed A; Weiss L
    AIDS; 2010 Mar; 24(6):867-73. PubMed ID: 20160635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance.
    Wei Y; Sluis-Cremer N
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722887
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of antiretroviral drug resistance.
    Wainberg MA; Zaharatos GJ; Brenner BG
    N Engl J Med; 2011 Aug; 365(7):637-46. PubMed ID: 21848464
    [No Abstract]   [Full Text] [Related]  

  • 20. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.